Colorectal Cancers are cancers that begin in the large intestine or rectum. Research has identified numerous germline and somatic mutations in 48 genes that are linked to cancers of the colon and rectum. Next Generation Sequencing (NGS) makes it possible to test the entire exonic regions of all 48 genes. In addition to these regions, our panel is designed to detect "hotspot" regions of 36 common tumor suppressors and oncogenes mutated in most cancers. Mutations in these genes provide important information regarding tumor development, tumor progression, and can be used as a reliable predictor of personalized cancer therapies. The Primbio Colorectal Cancer Panel uses the latest NGS technology to identify these mutations in both patients who have the initial phases of the disease (benign polyps) or are inflicted with advanced stages of the disease. With many mutations being clinically actionable, this panel can provide vital genetic information that can assist physicians in determining which is the best treatment regimen for their patients.